# Cerezyme (imiglucerase) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/imiglucerase

> The next catalyst for Cerezyme (imiglucerase), sponsored by Sanofi (SNY), is its topline data readout, Jan to Apr 2030.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Cerezyme (imiglucerase) |
| Codes |  |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | [Gaucher's Disease Type III](https://sec-api.dev/indications/gaucher-s-disease-type-iii), Gaucher Disease Type 1 |
| Modality | biologic |
| FDA designations | none disclosed |

## Timeline

### October 2, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Gaucher's Disease Type III.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05222906 (Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-02 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT05222906

### January 12, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA020367 SUPPL-123 (Efficacy): submission_status AP, submission_status_date 20260112, review_priority STANDARD; sponsor_name GENZYME; product CEREZYME (IMIGLUCERASE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA020367%22

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Gaucher Disease Type 1; Gaucher Disease Type 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02843035 (Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Genzyme, a Sanofi Company." https://clinicaltrials.gov/study/NCT02843035

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 2. Indication: Gaucher Disease Type 1; Gaucher Disease Type 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02843035 (Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Genzyme, a Sanofi Company." https://clinicaltrials.gov/study/NCT02843035

### Jan to Apr 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Gaucher's Disease Type III.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07927140 (The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-01-14 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07927140

### January 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Gaucher's Disease Type III.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07927140 (The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-01-14 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07927140

Calendar months: [October 2026](https://sec-api.dev/fda-calendar/2026-10)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/imiglucerase.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cerezyme (imiglucerase) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/imiglucerase

```bibtex
@misc{secapidev_pdufa_imiglucerase_20261116,
  title        = {Cerezyme (imiglucerase) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/imiglucerase}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_imiglucerase_20261116","title":"Cerezyme (imiglucerase) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/imiglucerase","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
